The levels of β-catenin, Bcl2, and CDK2 decreased in breast cancer cells treated with MeCP2 siRNAs compared to those with control siRNA, whereas the expression levels of Bax, P21, and P53 increased (Fig. 1k). The gene discussed is MECP2; the disease is breast carcinoma.